Cabio Biotech (Wuhan) Co., Ltd.

SHSE:688089 Stock Report

Market Cap: CN¥3.6b

Cabio Biotech (Wuhan) Management

Management criteria checks 3/4

Cabio Biotech (Wuhan)'s CEO is Dewei Yi, appointed in Dec 2015, has a tenure of 8.92 years. directly owns 1.39% of the company’s shares, worth CN¥50.43M. The average tenure of the management team and the board of directors is 8.9 years and 5.9 years respectively.

Key information

Dewei Yi

Chief executive officer

CN¥1.1m

Total compensation

CEO salary percentagen/a
CEO tenure8.9yrs
CEO ownership1.4%
Management average tenure8.9yrs
Board average tenure5.9yrs

Recent management updates

Recent updates

We Think That There Are Issues Underlying Cabio Biotech (Wuhan)'s (SHSE:688089) Earnings

Nov 04
We Think That There Are Issues Underlying Cabio Biotech (Wuhan)'s (SHSE:688089) Earnings

Cabio Biotech (Wuhan) (SHSE:688089) Might Be Having Difficulty Using Its Capital Effectively

Oct 28
Cabio Biotech (Wuhan) (SHSE:688089) Might Be Having Difficulty Using Its Capital Effectively

Subdued Growth No Barrier To Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) With Shares Advancing 31%

Oct 01
Subdued Growth No Barrier To Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) With Shares Advancing 31%

There's Reason For Concern Over Cabio Biotech (Wuhan) Co., Ltd.'s (SHSE:688089) Massive 25% Price Jump

Aug 06
There's Reason For Concern Over Cabio Biotech (Wuhan) Co., Ltd.'s (SHSE:688089) Massive 25% Price Jump

Cabio Biotech (Wuhan) (SHSE:688089) Could Be Struggling To Allocate Capital

Jun 07
Cabio Biotech (Wuhan) (SHSE:688089) Could Be Struggling To Allocate Capital

Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

May 06
Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

Cabio Biotech (Wuhan)'s (SHSE:688089) Promising Earnings May Rest On Soft Foundations

May 03
Cabio Biotech (Wuhan)'s (SHSE:688089) Promising Earnings May Rest On Soft Foundations

The Market Lifts Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Shares 27% But It Can Do More

Mar 21
The Market Lifts Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Shares 27% But It Can Do More

CEO

Dewei Yi (59 yo)

8.9yrs

Tenure

CN¥1,090,600

Compensation

Mr. Dewei Yi is Chairman and General Manager of CABIO Biotech(Wuhan) Co., Ltd., since December 2015. From December 1999 he has been the chairman of Wuhan Xiwang Biological Engineering Co., Ltd.; since Nove...


Leadership Team

NamePositionTenureCompensationOwnership
Dewei Yi
Chairman & GM8.9yrsCN¥1.09m1.39%
CN¥ 50.4m
Huabiao Wang
Financial Director & Director8.9yrsCN¥781.40k0.66%
CN¥ 24.0m
Huarong Yi
Deputy GM & Secretary of the Board of Directorsno dataCN¥640.10k0.089%
CN¥ 3.3m
Anfeng Geng
Deputy General Manager3.7yrsCN¥713.40k0.098%
CN¥ 3.6m
Zhiming Wang
Deputy General Manager2.9yrsCN¥862.90k0.14%
CN¥ 5.2m
Xiangyu Li
Deputy General Manager8.9yrsCN¥763.90k0.12%
CN¥ 4.4m
Tao Ma
Deputy General Manager8.9yrsCN¥640.90k0.093%
CN¥ 3.4m
Hao Xiong
Accounting Supervisorno datano datano data

8.9yrs

Average Tenure

48yo

Average Age

Experienced Management: 688089's management team is seasoned and experienced (8.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Dewei Yi
Chairman & GM8.9yrsCN¥1.09m1.39%
CN¥ 50.4m
Huabiao Wang
Financial Director & Director8.9yrsCN¥781.40k0.66%
CN¥ 24.0m
Bin Du
Vice Chairman8.9yrsCN¥984.80k0.58%
CN¥ 21.1m
Yujun Wu
Employee Representative Supervisor8.9yrsno data0.018%
CN¥ 661.5k
Chunyu Zhang
Director2.9yrsno datano data
Xiangdong Chen
Independent Director2.9yrsCN¥80.00kno data
Qi Liu
Independent Director2.9yrsCN¥80.00kno data
Jing Chen
Supervisor2.9yrsno datano data

5.9yrs

Average Tenure

53.5yo

Average Age

Experienced Board: 688089's board of directors are considered experienced (5.9 years average tenure).